Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2026)
Jaguar Health (JAGX) reported Income from Non-Controlling Interests of -$126000.0 for Q1 2026, up 4.55% year-over-year from -$120521.7 in Q1 2025, and up 4.55% quarter-over-quarter from -$132000.0 in Q1 2025.
Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$126000.0 in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at -$126000.0, up 4.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$536000.0 (up 2.37% YoY), and the FY2025 annual result was -$563000.0, up 25.82% from the prior year.
- Income from Non-Controlling Interests grew to -$126000.0 in Q1 2026 per JAGX's latest filing, from -$132000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$23000.0 in Q2 2022 and troughed at -$651000.0 in Q4 2022.
- A 5-year average of -$173166.7 and a median of -$137500.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 78.65% in 2023 and fell as far as 513.04% in 2023.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$651000.0 in 2022, then soared by 78.65% to -$139000.0 in 2023, then advanced by 2.16% to -$136000.0 in 2024, then grew by 2.94% to -$132000.0 in 2025, then grew by 4.55% to -$126000.0 in 2026.
- Business Quant data shows JAGX's Income from Non-Controlling Interests at -$126000.0 in Q1 2026, -$132000.0 in Q1 2025, and -$136000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | -126,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | -142,000.00 |
| Dec 31, 2023 | -139,000.00 |
| Sep 30, 2023 | -126,000.00 |
| Jun 30, 2023 | -141,000.00 |
| Mar 31, 2023 | -195,000.00 |
| Dec 31, 2022 | -651,000.00 |
| Sep 30, 2022 | -89,000.00 |
| Jun 30, 2022 | -23,000.00 |
| Mar 31, 2022 | -178,000.00 |